Cesarean Delivery Outcomes in Maternal Critical Care
- Sponsor
- Société Française d'Anesthésie et de Réanimation
- Study ID
- NCT07759024
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Delivery Complication
- Pregnancy Related
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Study Details
Cesarean delivery in critically ill pregnant women, especially outside the operating room, is a rare but high-risk situation for both mother and fetus. These patients often suffer from severe conditions (hypertensive disorders, hemorrhage, respiratory failure, infection, or trauma) and may require emergency cesarean in the ICU, emergency department, or prehospital setting. They frequently need advanced organ support and face higher rates of complications, prolonged ICU stay, and maternal mortality. Non-OR environments also create challenges in sterility, coordination, and management. Neonatal outcomes are often impaired by iatrogenic prematurity. Current evidence is limited. A large nationwide registry is needed to better describe outcomes and support future protocols and recommendations.
Key Dates
- First listed
- Aug 11, 2026
- Start date
- Oct 1, 2026
- Status verified
- Aug 2026
- Primary completion
- Dec 31, 2027
- Completion
- Dec 31, 2027
Study Design
- Enrollment
- 200 participants (estimated)
Arms
- Arm: Study group:• Study group: cesarean delivery performed outside the operating room (ICU, high-dependency unit, emergency department, or prehospital setting).
- Arm: Comparison group• Comparison group: women admitted to critical care without cesarean delivery outside the operating room, including: * cesarean delivery performed in the operating room; * women who did not undergo cesarean delivery.
- Arm: Descriptive subgroup:• Descriptive subgroup: women who died during pregnancy (≥22 weeks of gestation) without undergoing cesarean delivery.
Primary Outcome Measure
Maternal mortality [ Time Frame: during pregnancy or within 42 days after the end of pregnancy ]
Central Contacts
- Vincent LEGROS, MD+33 03 26 78 30 21
- Emilie RAIMOND, MD
Related Studies
- POWERMOM, A Healthy Pregnancy Research CommunityRecruiting · Scripps Translational Science Institute · La Jolla, California
- Maternal Autoimmune Disease Research Alliance (MADRA) RegistryRecruiting · Duke University · Durham, North Carolina
- Patient Centered Simulation For Labor and DeliveryNot Yet Recruiting · Wake Forest University Health Sciences · Winston-Salem, North Carolina
- Safety Study for Prospective Assessment of Pregnancy Outcomes in Patients Treated With TildrakizumabRecruiting · Sun Pharmaceutical Industries Limited · San Diego, California